A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Non-small-cell Lung
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. (in Cohort 2) Disease progressio...
This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
Tracking Information
- NCT #
- NCT03909971
- Collaborators
- Not Provided
- Investigators
- Study Director: Pfizer CT.gov Call Center Pfizer
Get Well Soon